STERIS plc
For the period ended Mar 31, 2025. Filed May 29, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed May 29, 2025
STE$257.12+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Years Ended March 31, | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating activities: | |||
| Net income | $616,074 | $380,079 | $105,813 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, depletion, and amortization | 476,215 | 565,244 | 552,897 |
| Deferred income taxes | (76,546) | (131,412) | (185,913) |
| Share-based compensation expense | 57,397 | 56,535 | 38,951 |
| Loss on the disposal of property, plant, equipment, and intangibles, net | 5,735 | 24,997 | 22,193 |
| Loss on classification as held for sale | — | 206,444 | — |
| Loss (gain) on sale of businesses and investments, net | 6,444 | 327 | (67) |
| Amortization of inventory fair value adjustments | — | 4,822 | 7,363 |
| Goodwill impairment loss | — | — | 490,565 |
| Other items | (3,745) | 12,316 | (24,832) |
| Changes in operating assets and liabilities, net of effects of acquisitions and divestitures: | |||
| Accounts receivable, net | (28,815) | (128,069) | (133,304) |
| Inventories, net | 73,072 | (37,450) | (123,921) |
| Other current assets | (50,272) | (1,552) | (24,086) |
| Accounts payable | 33,589 | (18,962) | 53,342 |
| Accruals and other, net | 38,939 | 39,955 | (22,054) |
| Net cash provided by operating activities | 1,148,087 | 973,274 | 756,947 |
| Investing activities: | |||
| Purchases of property, plant, equipment, and intangibles, net | (370,091) | (360,326) | (361,969) |
| Proceeds from the sale of property, plant, equipment, and intangibles | 9,195 | 7,381 | 14,587 |
| Proceeds from the sale of businesses | 814,558 | 9,458 | 6,624 |
| Proceeds from the sale of investments | — | 3,882 | — |
| Purchases of equity investments and convertible notes | (10,750) | (1,500) | — |
| Acquisition of businesses, net of cash acquired | (54,139) | (546,256) | (42,572) |
| Net cash provided by (used in) investing activities | 388,773 | (887,361) | (383,330) |
| Financing activities: | |||
| Payments on term loans | (638,125) | (60,000) | (156,875) |
| Payments on Private Placement Senior Notes | (80,000) | — | (91,000) |
| (Payments) proceeds under credit facilities, net | (446,304) | 181,486 | 241,657 |
| Deferred financing fees and debt issuance costs | (2,316) | — | — |
| Acquisition related deferred or contingent consideration | (355) | (6,242) | (1,471) |
| Repurchases of ordinary shares | (211,321) | (11,765) | (308,565) |
| Cash dividends paid to ordinary shareholders | (219,875) | (200,570) | (183,498) |
| Distributions to noncontrolling interest holders | (2,069) | (1,561) | (794) |
| Contributions from noncontrolling interest holders | 2,532 | 2,994 | — |
| Stock option and other equity transactions, net | 25,469 | 10,472 | 1,828 |
| Net cash used in financing activities | (1,572,364) | (85,186) | (498,718) |
| Effect of exchange rate changes on cash and cash equivalents | 185 | (2,064) | (14,862) |
| Decrease in cash and cash equivalents | (35,319) | (1,337) | (139,963) |
| Cash and cash equivalents at beginning of period | 207,020 | 208,357 | 348,320 |
| Cash and cash equivalents at end of period | $171,701 | $207,020 | $208,357 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.